Search alternatives:
significant substantial » significant potential (Expand Search), significant spatial (Expand Search)
substantial decrease » substantial increase (Expand Search)
increase decrease » increased release (Expand Search), increased crash (Expand Search)
significant substantial » significant potential (Expand Search), significant spatial (Expand Search)
substantial decrease » substantial increase (Expand Search)
increase decrease » increased release (Expand Search), increased crash (Expand Search)
-
1521
-
1522
Data Sheet 2_Ruxolitinib synergizes with regulatory T cells to improve inflammation but has no added benefits in decreasing albuminuria in SLE.pdf
Published 2025“…The addition of ruxolitinib increases UCB-Treg cell persistence in peripheral blood in vivo and decreases the soluble form of human inflammatory cytokines including IFN-γ, TNF-α, and sCD40L in plasma along with improvement of skin lesions in SLE xenografts. …”
-
1523
Data Sheet 3_Ruxolitinib synergizes with regulatory T cells to improve inflammation but has no added benefits in decreasing albuminuria in SLE.pdf
Published 2025“…The addition of ruxolitinib increases UCB-Treg cell persistence in peripheral blood in vivo and decreases the soluble form of human inflammatory cytokines including IFN-γ, TNF-α, and sCD40L in plasma along with improvement of skin lesions in SLE xenografts. …”
-
1524
Data Sheet 1_Ruxolitinib synergizes with regulatory T cells to improve inflammation but has no added benefits in decreasing albuminuria in SLE.pdf
Published 2025“…The addition of ruxolitinib increases UCB-Treg cell persistence in peripheral blood in vivo and decreases the soluble form of human inflammatory cytokines including IFN-γ, TNF-α, and sCD40L in plasma along with improvement of skin lesions in SLE xenografts. …”
-
1525
-
1526
-
1527
-
1528
-
1529
-
1530
-
1531
-
1532
-
1533
-
1534
-
1535
-
1536
-
1537
-
1538
-
1539
-
1540